PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | |infection |
| Sentences | 128 |
| PubMedID- 22970300 | Possession of certain genes and expression of their gene products may predispose different strains of h. influenzae to successful chronic infection in patients with cystic fibrosis or copd. |
| PubMedID- 23152277 | Selection criteria: randomized controlled trials of antibiotic therapy based on biofilm antimicrobial susceptibility testing compared to antibiotic therapy based on conventional antimicrobial susceptibility testing in the treatment of pseudomonas aeruginosa pulmonary infection in individuals with cystic fibrosis. |
| PubMedID- 22081229 | The identification of 17 b. dolosa genes that underwent selective pressure during infection in subjects with cystic fibrosis highlights key pathways involved in pathogenesis and may suggest new therapeutic targets for this and other lung infections. |
| PubMedID- 22551926 | Burkholderia cepacia complex (bcc) is a group of 17 closely related bacterial species that can cause pulmonary infection in patients with cystic fibrosis (cf). |
| PubMedID- 25068317 | Pseudomonas aeruginosa can grow to very high-cell-density (hcd) during infection of the cystic fibrosis (cf) lung. |
| PubMedID- 25596784 | cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. |
| PubMedID- 24696136 | Until such evidence becomes available, clinicians need to use their clinical judgement as to whether or not to treat stenotrophomonas maltophilia infection in patients with cystic fibrosis. |
| PubMedID- 25709717 | Similarly, emond and co-workers chose samples for exome sequencing based on the extremes of the first time to pseudomonas infection in individuals with cystic fibrosis. |
| PubMedID- 22592739 | However, the role of antibiotic treatment of stenotrophomonas maltophilia infection in people with cystic fibrosis is still unclear. |
| PubMedID- 21625534 | Therefore, in this study we have explored whether pleiotropic subcellular stressors and effects related to misfolded protein processing will mitigate barriers to infection using models of cystic fibrosis (cf). |
| PubMedID- 20837573 | Early pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified. |
| PubMedID- 23235684 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. |
| PubMedID- 22940004 | There is clear evidence some viral infections are associated with cystic fibrosis that dual infection is more likely to produce symptoms, and mechanisms of viral-induced exacerbation should be elucidated. |
| PubMedID- 25590621 | These results highlight a dynamic bacterial-host interaction between an opportunistic pathogen that causes chronic infections in the lungs of individuals with cystic fibrosis, an infection site known to be rich in neutrophil dna and neutrophil extracellular traps . |
| PubMedID- 21310671 | Anti-psa antibiotic therapy early in the course of psa infection in patients with cystic fibrosis (cf) may result in eradication of psa and prevention or delay of colonization with the organism. |
| PubMedID- 23737087 | Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. |
| PubMedID- 24510624 | Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 22364820 | Conclusion: genetic modifiers play a significant role in the establishment and timing of persistent pa infection in individuals with cystic fibrosis. |
| PubMedID- 25027419 | Rationale: pseudomonas aeruginosa (pa) serology could potentially be a useful adjunct to respiratory culture methods for the detection of initial or early pa infection in patients with cystic fibrosis (cf). |
| PubMedID- 20729233 | Background: initial pulmonary pseudomonas aeruginosa infection in patients with cystic fibrosis (cf) is currently treated with intensive antibiotic therapy. |
| PubMedID- 26442462 | Background: mycobacterium abscessus infection in patients with cystic fibrosis (cf) can result in accelerated clinical decline and the potential for direct or indirect transmission between patients has been recently demonstrated. |
| PubMedID- 26003071 | Aeruginosa in order to evaluate the epidemiological situation of this infection in patients with cystic fibrosis attending our centre; 2. |
| PubMedID- 21750293 | Context: early pulmonary infection in children with cystic fibrosis leads to increased morbidity and mortality. |
| PubMedID- 23066486 | Emergence of pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an iranian referral pediatric center. |
| PubMedID- 20097812 | The ubiquitous opportunistic human pathogen pseudomonas aeruginosa secretes a viscous extracellular polysaccharide, called alginate, as a virulence factor during chronic infection of patients with cystic fibrosis. |
| PubMedID- 20238363 | Objectives: to assess the effects of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. |
| PubMedID- 22216191 | It is also an emerging infection in patients with cystic fibrosis . |
| PubMedID- 24648553 | Trichosporon mycotoxinivorans infection in patients with cystic fibrosis. |
| PubMedID- 20137079 | Feasibility study to inform the design of a randomised controlled trial to eradicate pseudomonas aeruginosa infection in individuals with cystic fibrosis. |
| PubMedID- 23737089 | Authors' conclusions: we could not identify an antibiotic adjuvant therapy that could be recommended for the treatment of lung infection in those with cystic fibrosis. |
| PubMedID- 22683550 | P. aeruginosa is also responsible for pulmonary infection of patients with cystic fibrosis . |
| PubMedID- 24925006 | Eradication strategy for persistent methicillin-resistant staphylococcus aureus infection in individuals with cystic fibrosis--the pmep trial: study protocol for a randomized controlled trial. |
| PubMedID- 19996339 | Rationale: antibiotic therapy for early pseudomonas aeruginosa infection in patients with cystic fibrosis (cf) is effective, but the optimal therapeutic regimen and duration for early treatment remains unclear. |
| PubMedID- 20678316 | We report an outbreak of corynebacterium pseudodiphtheriticum infection in children with cystic fibrosis (cf). |
| PubMedID- 22916223 | Defective mucus secretion may result in failure of host defense against pathogens, which in turn could be the underlying pathogenesis of airway infection in patients with cystic fibrosis (cf) 2. |
| PubMedID- 26047157 | We used exome sequencing to identify variants in cav2 and tmc6 that modify the age-of-onset of chronic pseudomonas aeruginosa infection among children with cystic fibrosis, and validated our findings in a large cohort of children with cystic fibrosis. |
| PubMedID- 26543305 | Due to the progression, cystic fibrosis is inseparably associated with infection of lungs. |
| PubMedID- 23137712 | Treatment of lung infection in patients with cystic fibrosis: current and future strategies. |
| PubMedID- 19887136 | Vaccination against pseudomonas aeruginosa is a desirable, yet challenging strategy for prevention of airway infection in patients with cystic fibrosis. |
| PubMedID- 24260360 | A particularly serious medical problem caused by p. aeruginosa is chronic lung infection associated with cystic fibrosis . |
| PubMedID- 22084956 | Economic burden of pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 25034564 | Chronic airway infection in adults with cystic fibrosis (cf) is polymicrobial and the impact of intravenous antibiotics on the bacterial community composition is poorly understood. |
| PubMedID- 22119262 | Aims: to know the characteristics and prevalence of non-tuberculous mycobacterial infection infection in patients with non-cystic fibrosis bronchiectasis. |
| PubMedID- 25741986 | Selection criteria: randomized controlled trials of antibiotic therapy based on biofilm antimicrobial susceptibility testing compared to antibiotic therapy based on conventional antimicrobial susceptibility testing in the treatment of pseudomonas aeruginosa pulmonary infection in people with cystic fibrosis. |
| PubMedID- 24730990 | Bacteria of the burkholderia cepacia complex: epidemiology and diagnosis of infection in patients with cystic fibrosis. |
| PubMedID- 22540844 | In conclusion, these data underline the importance of biofilm prevention strategies by early aggressive antibiotic prophylaxis or therapy before phenotypic diversification during chronic lung infection of patients with cystic fibrosis. |
| PubMedID- 21067323 | Previously considered to have minimal inherent virulence owing to their commensal ability, the last decade has heralded an increasing recognition of candida infection among patients with cystic fibrosis. |
| PubMedID- 24324555 | However, p. aeruginosa is a significant cause of chronic infection and morbidity in patients with cystic fibrosis and chronic obstructive pulmonary disease, ventilator-associated pneumonia, and immunocompromised patients. |
| PubMedID- 25027418 | Pseudomonas aeruginosa infection is a hallmark of lung disease in cystic fibrosis. |
| PubMedID- 20951086 | Murine models of acute and chronic lung infection with cystic fibrosis pathogens. |